Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma

In this segment, Dr. Ajay Nooka opens the discussion by framing the evolving treatment landscape in relapsed and refractory multiple myeloma, followed by insights from Dr. Noopur Raje. The conversation highlights how treatment options have expanded significantly with the availability of proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies, yet challenges remain for patients who progress after exposure to these classes. Dr. Raje discusses the increasing complexity of treatment selection in multiple myeloma, particularly in later lines of therapy, where disease biology, prior treatment exposure, and durability of response play critical roles. The panel also addresses ongoing unmet needs, including patients with early relapse, high-risk disease features, and those with limited tolerance to therapy. This segment sets the stage for the broader discussion by emphasizing the need for continued innovation and individualized treatment strategies in relapsed and refractory multiple myeloma.